Icrucumab
Icrucumab (IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab has been studied in metastatic colon cancer.
Product Specifications
CAS Number
1024603-92-6
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
VEGFR
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
OR1050273-01 100 mg
Tert-Butyl 4- ((4-cyanopyridin-2-yl) thio) piperidine-1-carboxylate
Sign In for Pricing
View Details OR1050273-02 250 mg
Tert-Butyl 4- ((4-cyanopyridin-2-yl) thio) piperidine-1-carboxylate
Sign In for Pricing
View Details